FDA delays decision on Sarepta ’s gene therapy for Duchenne muscular dystrophy

The Food and Drug Administration is delaying by one month a decision on the approval of a gene therapy for Duchenne muscular dystrophy, the treatment’s maker, Sarepta Therapeutics, said Wednesday. Sarepta said the FDA expects to complete the review of its gene therapy called SRP-9001 by June 22. A…#sareptatherapeutics #sarepta #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news